文献速递免疫规划

四价流感疫苗在65岁及以上健康人群中的安全性与免疫原性

Safety and immunogenicity of a seasonal quadrivalent influenza vaccine (GC3110A) in healthy participants aged ≥ 65 years.
PubMed 文献 · Vaccine · 2021-05-13

本研究纳入274名65岁及以上健康参与者,接种季节性四价流感疫苗后21天评估4株流感病毒的血清转化和血清保护率,并监测不良事件至180天。结果显示各株血清转化率为36.5%至49.1%,血清保护率为81.2%至98.5%,未发生与研究疫苗相关的严重不良事件。结论认为四价裂解流感疫苗有望在老年人群中提供针对甲型和乙型流感谱系的血清保护。

要点

  • 65岁及以上健康人群接种四价流感疫苗后,各株血清保护率为81.2%至98.5%。
  • 各株血清转化率为36.5%至49.1%,未报告与研究疫苗相关的严重不良事件。
  • 四价裂解流感疫苗有望在老年人群中提供针对甲型和乙型流感谱系的血清保护。

核心结论

  • 四价裂解流感疫苗有望在老年人群中提供针对甲型和乙型流感谱系的血清保护。

研究设计与样本

  • 共274名65岁及以上健康参与者接种四价流感疫苗,接种后21天评估4株流感病毒的血清转化和血清保护,不良事件监测至接种后180天。

主要发现

  • 接种后对A/H1N1的血清转化率为36.5%(99/271),对A/H3N2为47.6%(129/271),对B Yamagata为40.6%(110/271),对B Victoria为49.1%(133/271)。
  • 接种后对A/H1N1的血清保护率为81.2%(220/271),对A/H3N2为98.5%(267/271),对B Yamagata为95.2%(258/271),对B Victoria为93.7%(254/271)。
  • 未发生与研究疫苗相关的严重不良事件。

临床怎么用

  • 在65岁及以上健康人群中,四价流感疫苗可考虑用于提供针对甲型和乙型流感谱系的血清保护。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Seasonal Influenza is still considered associated with seasonal morbidity and hospitalization in the elderly population. The World Health Organization (WHO) recommended seasonal quadrivalent influenza vaccine (QIV) to reduce burden of two currently circulating influenza B lineages. Until 2019 Korean National Immunization Program (NIP) recommended trivalent influenza vaccine (TIV) after ongoing debates on cost effectiveness of QIV for elderly population. Although influenza vaccine only showed modest effect on reducing influenza in elderly, this study aimed to evaluate the immunogenicity and safety of inactivated QIV in healthy participants ≥ 65 years of age. METHODS: A total of 274 healthy participants aged ≥ 65 years received a QIV. Seroconversion-based vaccine efficacy of 4 strains of seasonal influenza was assessed 21 days after vaccination and adverse events were monitored until 180 days after vaccination. RESULTS: The percentages of participants seroconverted after vaccination on HI antibody against each strain were 36.5% (99/271) to A/H1N1, 47.6% (129/271) to A/H3N2, 40.6% (110/271) to B Yamagata, and 49.1% (133/271) to B Victoria. The percentages of participants seroprotected after vaccination on HI antibody against each strain were 81.2% (220/271) to A/H1N1, 98.5% (267/271) to A/H3N2, 95.2% (258/271) to B Yamagata, and 93.7% (254/271) to B Victoria. There was no serious adverse event (SAE) related with the study vaccine. CONCLUSION: The quadrivalent split influenza vaccine is expected to offer seroprotection against influenza A and both influenza B lineages even in the elderly population.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Kim TH, Choi JH, Park SH, et al. Safety and immunogenicity of a seasonal quadrivalent influenza vaccine (GC3110A) in healthy participants aged ≥ 65 years. Vaccine. 2021. PMID: 33992436. doi:10.1016/j.vaccine.2021.05.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。